SIOX: Sio Gene Therapies Inc. - Summary | Jitta

Sio Gene Therapies Inc.

NASDAQ:SIOX

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.48
Loss Chance
58.4%
0.59JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (8)
Recent Business Performance (17)
Financial Strength (30)
Return to Shareholders (0)
Competitive Advantage (6)
Jitta Signs
SG&A to SalesDecreasing Every Year
Cash Conversion CycleLess than 30 days
Recent Business PerformanceEarning decline 50.02% in the last year
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.59
100.00%
2.21
131.14%
3.05
162.56%
Biotechnology
6.36
42.66%
4.69
49.83%
3.69
93.14%
COMPANY DESCRIPTION
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.